Aurora Cannabis Inc. · TSX:ACB
Aurora Cannabis — Q3 2025 Earnings Presentation
19 slides from Aurora Cannabis's earnings presentation, Feb 5, 2025
Slide 1: Investor Presentation FY25 Q3
INVESTOR PRESENTATION FY25 Q3 February 2025
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed
Slide 3: Diversified Global Business Model
Diversified Global Business Model Focus on Defensive, Stable, High Margin Segments International Canadian Medical Plant Propagation Adult Recreational Science & Innovation Medical #1 Canadian Medical Net revenue increased 22% in Q3 Ability to deliver products Delivering a continuous stream share by
Slide 4: Leading Global Cannabis Platform
Leading Global Cannabis Platform • Global medical cannabis net revenue(1) reached a record $68.1m in Q3, up 51% compared to the prior year period. • Increased revenue primarily attributable to increasing sales in Canada, Germany, Australia, Poland and the UK. • Adjusted gross margins(1) for medical
Slide 5: Leadership in Key Global Cannabis Markets
Leadership in Key Global Cannabis Markets POLAND: 40m population UNITED KINGDOM: 68m population • Rapidly growing medical market • Strong market position through relationships with key distributors and supply of Channel Islands; a • Aurora consistently maintains top 3 market share high-growth market
Slide 6: European Medical Leadership
European Medical Leadership Aurora is a leader in the German, Polish and UK markets due to a consistent supply of high quality EU GMP cannabis products. Aurora Product Range Consistent Revenue Stream and Margin Leader PEDANIOS 31/1COS-CA • Aurora Europe posted another record quarter of revenues in Q
Slide 7: Australia & New Zealand Market Leadership
Australia & New Zealand Market Leadership Following the acquisition of MedReleaf Australia, the # 2 player in the market, Aurora has expanded its medical product portfolio, to meet the growing needs of the patients in Australia and New Zealand. Consistent Revenue Stream, Margin Leader and new market
Slide 8: FY25 Product Launches: Australia & New Zealand
FY25 Product Launches: Australia & New Zealand To date in FY25, 28 new SKUs have been launched in Australia and New Zealand, covering a wide range of formats and catering to multiple patient segments. In Q3, 5 oils under the Aurora brand launched – providing Australian patients with a larger selecti
Slide 9: Canadian Medical Leadership
Canadian Medical Leadership Aurora is leading the market with four owned brands and a wide variety of marketplace offerings. Aurora partnered with Vectura Fertin Pharma to launch LUO TM, an innovative CBD lozenge Consistent Revenue Stream and Margin Leader • #1 Canadian Medical Share by revenue; ~6%
Slide 10: Visit our new Auroramedical.com website
Visit our new Auroramedical.com website Customer benefits • More intuitive design tailored to segments • Find products faster with enhanced search and filters • Compare similar products quickly • Get personalized recommendations • Love a product? Save it on your new wish list so you never forget a f
Slide 11: Latest Canadian Medical Innovations
Latest Canadian Medical Innovations Dried Flower Lotions & Topicals Oils & Capsules Edibles & Beverages Vapes & Concentrates • WMMC Kootna Kush • Arctic Heat Cream • Coming Soon: • Being CBD Golden Guava • Aurora Medical Solara 510 • WMMC Pomelo Fresco • Arctic Heat Relief stick o Medreleaf Equiberr
Slide 12: A Compelling Portfolio of Adult Recreational Brands
A Compelling Portfolio of Adult Recreational Brands Core Alternative Premium Super Premium Maximum Flavour, Maximum Potency, High-THC edibles for the Proprietary genetics with unique aromas Exceptional true-to-cultivar, craft offerings. Brand Promise Maximum Value modern-day consumer in a range of s
Slide 13: Sales and Marketing Support
Sales and Marketing Support Ongoing national campaign focused on maximizing brand and product Innovation will be communicated to retailers via national e-mail and in- awareness, further enhancing purchase consideration for Tasty's Vapes. store pitches. They will be supported by a full suite of digit
Slide 14: Plant Propagation Overview
Plant Propagation Overview • Aurora holds a controlling interest in Bevo Farms, an industry leader in plant propagation and one of the largest suppliers of propagated vegetables and ornamental plants in North America. • Bevo is cash flow positive on an annualized basis and contributed strong revenue
Slide 15: Science & Innovation Program
Science & Innovation Program A state-of-the-art breeding facility in Vancouver Island’s Comox Valley: • Built specifically to develop the next big cultivars: high potency, with excellent bud structure and density, highly aromatic and expressing unique terpene profiles sought by patients and consumer
Slide 16: Key Takeaways
Key Takeaways Opening the Largest global medical cannabis company in nationally legal markets World to Diversified and growing footprint in high-margin medical cannabis markets across the globe Cannabis Consistent sequential and year-over-year revenue growth, including record global medical re
Slide 17: Senior Management Team
Senior Management Team Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Simona King Nathalie Clark Alex Miller Chief Financial Offic
Slide 18: Board of Directors
Board of Directors Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Norma Beauchamp Theresa Firestone Ronald Funk Director Director
Slide 19: Investor Presentation
INVESTOR PRESENTATION Email: aurora@icrinc.com Website: auroramj.com/investors